In June 2020, Elmiron manufacturer Janssen Pharmaceuticals updated the drug’s product label to the warning of vision problems. It also recommended that the people who use Elmiron should have their eyesight tested regularly.
The label now declares that Elmiron can change pigments in the retina, cause blurred vision, reading problems, and make you sensitive to low light.
The label moreover mentions that a patient’s eyesight can continue to get worse even if they have stopped using Elimron. These changes are irreversible.
While this warning can prove to be helpful for the future Elmiron users, it has come too late for those who are already suffering from eye damage.